ClinicalTrials.gg
WithdrawnNCT07670403DP-SKINUpdated Oct 16, 2026

Digital Phenotyping of Psychological Distress in Skin Cancer Patients

An observational study in Skin Cancer, Melanoma (Skin Cancer) and Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), sponsored by West China Hospital. Withdrawn at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by West China Hospital · Observational

How we know · 2 judgments

Why this study was withdrawn
poor accrual
Updated Oct 16, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This prospective observational study enrolls 500 skin cancer patients across five Chinese tertiary care centers. The investigators use natural language processing and a hierarchical transformer model to analyse 1.2 million social media posts (Weibo, Douyin, Xiaohongshu, WeChat) for psychological distress and suicide ideation, with prospective validation of an AI Early Warning System.

Read the detailed description

Skin cancer patients experience high rates of anxiety and depression, yet routine screening is inconsistent. This study collects social media content from 500 patients over 24 months (12 months retrospective + 12 months prospective). Linguistic markers are identified using a custom Skin Cancer Linguistic Inquiry and Word Count (SC-LIWC) dictionary developed through expert consensus. A hierarchical transformer network with multi-head self-attention is built, comprising word-level (RoBERTa-wwm-ext), post-level (BiGRU+attention), and user-level (8-head self-attention) encoders with platform embeddings to address cross-platform heterogeneity. The model predicts suicide ideation risk (C-SSRS score ≥2) within 12 months, achieving AUC=0.91 in validation. An AI Early Warning System (EWS) is prospectively tested: alerts are triggered at threshold 0.38, reviewed by psychologists (12.4 min/alert), and interventions (crisis hotline, online counselling, psychoeducational materials) are automatically delivered. All data collection complies with China's Personal Information Protection Law (PIPL) and uses a 5-layer de-identification protocol (direct identifier removal, SHA-256 hashing, NER redaction, timestamp shifting, role-based access control). The study also examines cross-platform performance, optimal observation windows, and false-positive patterns to guide refinement

02

Conditions studied

  • Skin Cancer
  • Melanoma (Skin Cancer)
  • Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
  • Basal Cell Carcinoma of Skin

Keywords

  • digital phenotyping; psychological distress; social media; natural language processing; transformer; suicide prevention; psycho-oncology
03

In context

Skin Neoplasms

606 studies on the registry are indexed under Skin Neoplasms; 127 are open to participants now.

Browse Skin Neoplasms studies →

Lead sponsor

West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Skin cancer patients experience high rates of anxiety and depression, yet routine screening is inconsistent. This study collects social media content from 500 patients over 24 months (12 months retrospective + 12 months prospective).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. confirmed skin cancer within the preceding 60 months
  3. Active user of at least one target social media platform (Weibo, Douyin, Xiaohongshu, or WeChat Channels)
  4. Willingness to provide for social media data collection
  5. Ability to read and write in Chinese

Exclusion criteria

Exclusion Criteria:

  1. Pre-existing major psychiatric disorder diagnosed prior to cancer diagnosis
  2. Cognitive impairment preventing
  3. Inability to access social media accounts
  4. Concurrent participation in other digital mental health interventions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • cancer patients across five Chinese tertiary care centers
06

What researchers measure

Primary outcomes

  1. Incidence of Suicide Ideation Risk Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Proportion of participants with C-SSRS score ≥ 2 (active suicidal ideation with some intent to act, without specific plan) at any follow-up assessment. The C-SSRS is a clinician-administered instrument with a severity subscale ranging from 0 (no suicidal ideation) to 5 (active suicidal ideation with specific plan and intent). Higher scores indicate greater suicide risk.

    Time frame: 24 months

Secondary outcomes

  1. Depression Severity Assessed by the Patient Health Questionnaire-9 (PHQ-9)

    Mean change in PHQ-9 total score from baseline to each follow-up assessment. The PHQ-9 is a 9-item self-report questionnaire measuring depressive symptoms over the past 2 weeks. Total scores range from 0 to 27, with higher scores indicating greater depression severity (moderate-to-severe: ≥10).

    Time frame: 24 months

  2. Anxiety Severity Assessed by the Generalized Anxiety Disorder-7 (GAD-7)

    Mean change in GAD-7 total score from baseline to each follow-up assessment. The GAD-7 is a 7-item self-report questionnaire measuring generalized anxiety symptoms over the past 2 weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity (moderate-to-severe: ≥10).

    Time frame: 24 months

  3. Psychological Distress Assessed by the Hospital Anxiety and Depression Scale (HADS)

    Mean change in HADS total score (sum of Anxiety and Depression subscales) from baseline to each follow-up assessment. The HADS is a 14-item self-report questionnaire with two 7-item subscales (Anxiety and Depression), each ranging from 0 to 21. Higher subscale scores indicate worse psychological distress (subscale ≥15 indicates clinically significant distress).

    Time frame: 24 months

  4. Rate of Psychological Resource Utilization Following AI Early Warning System Alerts

    Proportion of high-risk participants (C-SSRS ≥ 2) who access at least one psychological resource (crisis hotline, online counseling link, or psychoeducational material) following an automated alert from the AI Early Warning System, compared to a matched historical control group (pre-EWS period).

    Time frame: 24 months

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Dec 2025, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 26, 2026
StartActual
Jan 1, 2024
Primary completionActual
Dec 30, 2025
CompletionActual
Jun 1, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Withdrawn poor accrual
changed Oct 16, 2026
Enrollment
500→0
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Completed→Withdrawn
    Why stopped poor accrual
    Enrollment 500→0
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07670403
Responsible party
Zhigang Lan (Professor, West China Hospital) — Principal investigator
First posted
Jun 26, 2026
Start date
Jan 1, 2024
Primary completion
Dec 30, 2025
Completion
Jun 1, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion